Latest From Zogenix Inc.
EMD Serono’s multiple sclerosis drug joins small cadre of products that survived a refuse to file letter and NDA withdrawal; chart details recent RTFs and application withdrawals.
Keeping Track: NME Approvals For Evenity And Balversa; Non-NME Approvals For Dovato And Keytruda; But An RTF For Fintepla
Zogenix seems only to have itself to blame for an unexpected refusal to file letter from the US agency for its novel treatment for Dravet syndrome that sent its shares tumbling by 31% on NASDAQ in after-hours trading.
- Specialty Pharmaceuticals
- Therapeutic Areas
- Neurology, Nervous System
- SJ2 Therapeutics Inc.
- North America
- Parent & Subsidiaries
- Zogenix Inc.
- Senior Management
Stephen J Farr, PhD, Pres. & CEO
Michael P Smith, EVP, CFO, Treasurer & Secretary
Bradley S Galer, MD, EVP, CMO
Gail M Farfel, PhD, EVP, Chief Dev. Officer
Ashish Sagrolikar, EVP, Chief Commercial Officer
- Contact Info
Phone: (858) 259-1165
5858 Horton St.
Emeryville, CA 94608
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.